Equillium (NYSE:EQ) Given “Buy” Rating at HC Wainwright

Share on StockTwits

HC Wainwright restated their buy rating on shares of Equillium (NYSE:EQ) in a research note issued to investors on Tuesday morning, AnalystRatings.com reports. They currently have a $14.00 target price on the stock.

“We have assessed Equillium using a risk-adjusted net present value (rNPV) approach driven by a discounted cash flow (DCF) analysis. This yields a $326M total firm value, driven by the future royalty-based revenue from itolizumab in GvHD and asthma. We apply a discount rate of 12% and effective tax rate of 30% to all future cash flows. This translates into a price per share of $14, assuming 22.8M shares outstanding as of mid-2020.”,” HC Wainwright’s analyst wrote.

Separately, Zacks Investment Research raised Equillium from a sell rating to a hold rating in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $17.75.

Equillium stock opened at $3.76 on Tuesday. The firm has a 50 day moving average price of $4.98. Equillium has a 1 year low of $3.10 and a 1 year high of $19.69.

Equillium (NYSE:EQ) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.04.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC acquired a new stake in Equillium during the 4th quarter valued at approximately $6,994,000. BlackRock Inc. acquired a new stake in Equillium during the 4th quarter valued at approximately $1,756,000. Victory Capital Management Inc. increased its position in Equillium by 7.4% during the 1st quarter. Victory Capital Management Inc. now owns 1,323,381 shares of the company’s stock valued at $10,587,000 after purchasing an additional 90,792 shares during the period. Northern Trust Corp acquired a new stake in Equillium during the 4th quarter valued at approximately $298,000. Finally, Geode Capital Management LLC acquired a new stake in Equillium during the 4th quarter valued at approximately $143,000.

About Equillium

Equillium, Inc, a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Recommended Story: Investing strategies using the yield curve

Analyst Recommendations for Equillium (NYSE:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Eversept Partners LP Has $15.71 Million Stake in Ascendis Pharma A/S
Amarin Co. plc  Stock Holdings Lessened by Eversept Partners LP
Amarin Co. plc Stock Holdings Lessened by Eversept Partners LP
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Cuts Stock Holdings in Sanofi SA
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Makes New $6.32 Million Investment in Alnylam Pharmaceuticals, Inc.
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Buys 8,930 Shares of argenx SE –
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.
Eversept Partners LP Has $20.76 Million Holdings in Danaher Co.


© 2006-2019 Ticker Report